PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for patients who are...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane Database Syst Rev
Main Authors: Schmidt, Amand F, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, Juan P
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2017
Subjects:
Medicine General & Introductory Medical Sciences
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478267/
https://ncbi.nlm.nih.gov/pubmed/28453187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items